Nasdaq
$27.74▲ 2.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.08BShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
26- 10.7After-hours26.10.08 05:004Ownership#●●●
Amylyx Pharmaceuticals, Inc.
George M. Milne Jr., a director at Amylyx Pharmaceuticals, reported a change in beneficial ownership of securities as of October 5, 2026. This filing is a Form 4 statement detailing the insider's equity activity.…more
$27.74+2.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:38144Ownership
Amylyx Pharmaceuticals, Inc.
George M. Milne Jr., a director at Amylyx Pharmaceuticals, has filed a Form 144 regarding the proposed sale of company shares. This is a standard regulatory filing disclosing an insider's plan to dispose of shares.…more
$27.74+2.06%vs prev closeView filingShare - 9.14After-hours26.09.15 05:004Ownership
Amylyx Pharmaceuticals, Inc.
Camille L. Bedrosian, an executive at Amylyx Pharmaceuticals, reported a change in beneficial ownership of company securities effective September 10, 2026. This filing serves as a standard Form 4 disclosure regarding insider stock holdings.…more
$27.74+2.06%vs prev closeView filingShare
25 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6Pre-market26.10.06 21:07#●●●#●●●
Amylyx Pharma to Present Phase 3 Data for Avexitide at ObesityWeek 2026…more
Amylyx Pharmaceuticals will present topline results from its Phase 3 LUCIDITY trial for avexitide, a treatment for post-bariatric hypoglycemia. As there are currently no FDA-approved therapies for this condition, the presentation of these clinical results is a significant milestone for the company.…more
$27.74+2.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.20Overnight26.08.20 14:26
●●●●●●●● ●●●●● ●●●●●●
Amylyx Pharmaceuticals has priced a public offering of 14.09 million common shares at $35.50 per share to raise $500 million. This significant equity financing is expected to result in shareholder dilution.…more
$27.74+2.06%vs prev closeShareBenzinga - 8.18After-hours26.08.19 05:02
●●●●●●●● ●●●●● ●●●●●●
Amylyx Pharmaceuticals has announced a $350 million common stock offering to raise capital. This move is likely to be viewed negatively by investors due to the potential dilution of existing shareholder value.…more
$27.74+2.06%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report